Researchers studied 282 subjects: 78 had colorectal cancer, 65 had advanced adenomas, 39 had other cancers and 100 had no colorectal lesions. The test had a specificity of 88 percent and a sensitivity of 83 percent.
The company is hoping to build off this trial with a prospective colon cancer clinical validation trial that it plans to enroll more than 1,600 subjects into. The results from that trial could be used to validate the company’s newly formed noninvasive colon cancer test.
More articles on surgery centers:
6 spine-focused ASCs opened or announced this year
The 10 best states for healthcare l 2019
Physician-managed Altair Health opens spine ASC — 3 insights
